Signet Investment Advisory Group Inc. Purchases 189 Shares of Bristol-Myers Squibb (NYSE:BMY)

Signet Investment Advisory Group Inc. lifted its holdings in Bristol-Myers Squibb (NYSE:BMY) by 2.3% in the fourth quarter, HoldingsChannel reports. The firm owned 8,261 shares of the biopharmaceutical company’s stock after purchasing an additional 189 shares during the quarter. Signet Investment Advisory Group Inc.’s holdings in Bristol-Myers Squibb were worth $467,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of BMY. AMF Tjanstepension AB grew its position in Bristol-Myers Squibb by 6.9% in the third quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock worth $31,618,000 after acquiring an additional 39,419 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Bristol-Myers Squibb by 18.1% in the 3rd quarter. Exchange Traded Concepts LLC now owns 26,468 shares of the biopharmaceutical company’s stock valued at $1,369,000 after purchasing an additional 4,064 shares during the last quarter. Sound Income Strategies LLC boosted its holdings in shares of Bristol-Myers Squibb by 46.9% in the 3rd quarter. Sound Income Strategies LLC now owns 2,770 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 885 shares during the period. Thurston Springer Miller Herd & Titak Inc. increased its position in shares of Bristol-Myers Squibb by 22.8% during the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 4,532 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 840 shares during the last quarter. Finally, Procyon Advisors LLC raised its holdings in Bristol-Myers Squibb by 3.4% during the 3rd quarter. Procyon Advisors LLC now owns 17,237 shares of the biopharmaceutical company’s stock valued at $891,000 after buying an additional 572 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 0.8 %

NYSE:BMY opened at $55.99 on Wednesday. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $61.10. The company has a 50-day moving average of $57.48 and a 200 day moving average of $53.97. The firm has a market cap of $113.56 billion, a PE ratio of -12.67, a price-to-earnings-growth ratio of 2.13 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.81%. As a group, research analysts anticipate that Bristol-Myers Squibb will post 6.75 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were issued a $0.62 dividend. The ex-dividend date was Friday, January 3rd. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.43%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -56.11%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on BMY shares. Sanford C. Bernstein assumed coverage on shares of Bristol-Myers Squibb in a research report on Thursday, October 17th. They set a “market perform” rating and a $56.00 price objective on the stock. Morgan Stanley upped their price target on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. Leerink Partners upgraded Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $55.00 to $73.00 in a research report on Tuesday, November 12th. Wells Fargo & Company increased their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a report on Friday, February 7th. Finally, Daiwa Capital Markets upgraded Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a report on Wednesday, November 13th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.